Literature DB >> 6259204

Antigenically intermediate human adenovirus strain associated with conjunctivitis.

J C Hierholzer, F H Rodriguez.   

Abstract

Two strains of an antigenically intermediate human adenovirus were isolated from eye specimens from cases of conjunctivitis. The viruses were doubly neutralized by antisera to adenoviruses 15 and 29 but possessed the hemagglutinins of adenovirus 8 or 9.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6259204      PMCID： PMC273797          DOI： 10.1128/jcm.13.2.395-397.1981

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  17 in total

1.  Isolation of adenovirus type 29 from an outbreak of epidemic keratoconjunctivitis.

Authors:  V Kasová; M Brůcková; F Kotelenský; K Kotelenská; R Ulrichová
Journal:  Acta Virol       Date:  1977-03       Impact factor: 1.162

Review 2.  Adenoviruses. Status of current knowledge.

Authors:  R Sohier; Y Chardonnet; M Prunieras
Journal:  Prog Med Virol       Date:  1965

3.  Further subgrouping of the human adenoviruses by differential hemagglutination.

Authors:  J C Hierholzer
Journal:  J Infect Dis       Date:  1973-10       Impact factor: 5.226

4.  Observations on two new adenovirus serotypes with unusual antigenic characteristics.

Authors:  N R Blacklow; M D Hoggan; J B Austin; W P Rowe
Journal:  Am J Epidemiol       Date:  1969-12       Impact factor: 4.897

5.  Immunological basis of the adenovirus 8-9 cross-reaction.

Authors:  J C Hierholzer; W R Dowdle
Journal:  J Virol       Date:  1970-12       Impact factor: 5.103

6.  Standardized viral hemagglutination and hemagglutination-inhibition tests. II. Description and statistical evaluation.

Authors:  J C Hierholzer; M T Suggs; E C Hall
Journal:  Appl Microbiol       Date:  1969-11

7.  Reference equine antisera to 33 human adenovirus types: homologous and heterologous titers.

Authors:  J C Hierholzer; W C Gamble; W R Dowdle
Journal:  J Clin Microbiol       Date:  1975-01       Impact factor: 5.948

8.  New human adenovirus isolated from a renal transplant recipient: description and characterization of candiate adenovirus type 34.

Authors:  J C Hierholzer; N O Atuk; J M Gwaltney
Journal:  J Clin Microbiol       Date:  1975-04       Impact factor: 5.948

9.  The Seattle Virus Watch. VII. Observations of adenovirus infections.

Authors:  J P Fox; C E Hall; M K Cooney
Journal:  Am J Epidemiol       Date:  1977-04       Impact factor: 4.897

10.  Infections in 18,000 infants and children in a controlled study of respiratory tract disease. I. Adenovirus pathogenicity in relation to serologic type and illness syndrome.

Authors:  C D Brandt; H W Kim; A J Vargosko; B C Jeffries; J O Arrobio; B Rindge; R H Parrott; R M Chanock
Journal:  Am J Epidemiol       Date:  1969-12       Impact factor: 4.897
View more
  4 in total

1.  Computational analysis and identification of an emergent human adenovirus pathogen implicated in a respiratory fatality.

Authors:  Christopher M Robinson; Gurdeep Singh; Cécile Henquell; Michael P Walsh; Hélène Peigue-Lafeuille; Donald Seto; Morris S Jones; David W Dyer; James Chodosh
Journal:  Virology       Date:  2010-11-05       Impact factor: 3.616

2.  Immunological relationship among human adenoviruses of subgenus D.

Authors:  R Wigand; D Keller; I Werling
Journal:  Arch Virol       Date:  1982       Impact factor: 2.574

3.  Analysis of antigenically intermediate strains of subgenus B and D adenoviruses from AIDS patients.

Authors:  J C Hierholzer; T Adrian; L J Anderson; R Wigand; J W Gold
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

4.  Computational and serologic analysis of novel and known viruses in species human adenovirus D in which serology and genomics do not correlate.

Authors:  Elizabeth B Liu; Debra A Wadford; Jason Seto; Maria Vu; Nolan Ryan Hudson; Lisa Thrasher; Sarah Torres; David W Dyer; James Chodosh; Donald Seto; Morris S Jones
Journal:  PLoS One       Date:  2012-03-13       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.